Last reviewed · How we verify

VGN-R08b 8.4×10^13 vg

Shanghai Vitalgen BioPharma Co., Ltd. · Phase 1 active Small molecule

VGN-R08b 8.4×10^13 vg is a Small molecule drug developed by Shanghai Vitalgen BioPharma Co., Ltd.. It is currently in Phase 1 development.

At a glance

Generic nameVGN-R08b 8.4×10^13 vg
SponsorShanghai Vitalgen BioPharma Co., Ltd.
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about VGN-R08b 8.4×10^13 vg

What is VGN-R08b 8.4×10^13 vg?

VGN-R08b 8.4×10^13 vg is a Small molecule drug developed by Shanghai Vitalgen BioPharma Co., Ltd..

Who makes VGN-R08b 8.4×10^13 vg?

VGN-R08b 8.4×10^13 vg is developed by Shanghai Vitalgen BioPharma Co., Ltd. (see full Shanghai Vitalgen BioPharma Co., Ltd. pipeline at /company/shanghai-vitalgen-biopharma-co-ltd).

What development phase is VGN-R08b 8.4×10^13 vg in?

VGN-R08b 8.4×10^13 vg is in Phase 1.

Related